Compugen (NASDAQ:CGEN) dosed the first patient in its Phase 1 trial of COM701, in combination with Opdivo, in patients with advanced solid tumors.
The Phase 1 study will assess the safety and tolerability of COM701, a therapeutic antibody targeting the novel immune checkpoint, PVRIG. The study will also assess COM701 in combination with the PD-1 inhibitor, Opdivo, which will be provided by Compugen’s development partner, Bristol-Myers Squibb.
“As a first-in-class drug candidate against a novel drug target backed by a solid biological rationale and biomarker strategy, COM701 has generated interest in our Phase 1 study,” said Anat Cohen-Dayag, Compugen’s president and CEO, said in statement.
“We look forward to exploring the clinical potential of the therapy to improve response rates in patients with refractory or relapsed disease across multiple indications,” she added.
The study currently has 10 participating sites and expects to enroll some 140 patients in 2019.
